Introduction
The incidence of thromboembolism is particularly high after total hip replacement. Deep vein thrombosis occurs in up to 70% of patients. ' The incidence of the postphlebitic limb syndrome complicating thrombosis after hip replacement is unknown but may be as high as 51%, which occurs after long bone fractures.2 Subclinical pulmonary emboli occur in up to 23% of patients,3 and 1-2% of patients die of pulmonary embolism. 4 Many prophylactic regimens have been described but none have proved ideal and there is no consensus on the most suitable prophylaxis.' Several studies found that low dose heparin was effective,67 but Sikorski et al suggested that this regimen may only delay the onset of thromboembolic complications, describing a rebound surge in thromboembolism once heparin was stopped.' Other studies found low dose heparin to be ineffective."' Conventional full dose anticoagulation begun before surgery is highly effective in preventing thromboembolism" but has never been widely accepted because of the risks.4
A recent report of the success of fixed minidose warfarin in gynaecological patients'2 prompted us to test its efficacy after total hip replacement. The advantages of this simple regimen were that there were no haemorrhagic complications; prescription was by a daily fixed dose; and prophylaxis was continued after discharge from hospital, covering the period when 60% of fatal pulmonary emboli are likely to occur. II 
Patients and methods
The study was modelled on projected estimations from the report of Poller et al. ' 2 We were seeking to detect a reduction in deep vein thrombosis from 50% to 20%. For the power ofthe study (1) (2) (3) 5 MHz transducer.'4 A significant haematoma was judged to be one calculated to be more than 20 ml. Follow up-All patients were reviewed six weeks after operation to ascertain whether any thromboembolic episodes had occurred since discharge.
Results
The treatment and control groups were comparable with respect to age, sex, obesity score, type of joint replacement, operative time, diagnosis, prevalence of varicose veins, and surgical approach (table I) . Blood loss, transfused blood volume, haemoglobin deficit, and incidences of wound sepsis and haematoma were also similar (table II) . Deep vein thrombosis was detected in 34% of patients (n=25) in the treatment group and 26% of patients (n= 19) in the control group (difference 8%; 95% confidence interval -6-8% to 22-8%).
Discussion
The '25I-fibrinogen technique was used in this trial to detect deep vein thrombosis because it offers a safe method of observing thromboembolic activity in the leg veins over a prolonged period. A modification ofthe original technique of Kakkar et all3 was used as described by Hampson et al.'0 Because of its relative inaccuracy in the femoral vein segment any suggestion of an abnormal scan count in that segment was followed with a phlebogram before deep vein thrombosis was confirmed.
We found that a prophylactic regimen using 1 mg warfarin daily perioperatively had no effect on the incidence offibrinogen positive scans in the leg veins of patients having total hip replacement. The overall rate of thrombosis was 30%, which was considerably lower than the collective mean incidence of 59% gleaned from 14 studies in the 1970s.' The difference may reflect the more modern practice of early mobilisation and shorter operating times.
The confusion on the issue of prophylaxis against deep vein thrombosis after total hip replacement is reflected by the current policy of prophylaxis used by British orthopaedic surgeons. Some 50 4% still take no routine prophylactic precautions for their patients and only 19-4% use anticoagulants. 5 Our findings support the thesis that deep vein thrombosis after total hip replacement is more resistant to prevention than deep vein thrombosis after other types of surgery. We conclude that fixed minidose warfarin is unlikely to afford any useful prophylaxis against complications of thromboembolism in patients having total hip replacement and therefore that this regimen cannot be recommended for prophylaxis in these patients.
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